Some basic questions, concerning the monitoring conditions, the monitoring and early warning index and technology system, and the selection basis for monitoring points and layers were discussed.
Therefore, such diagnostic procedures may prove useful for patient selection or for monitoring the progress of treatment with long circulating nanoparticles carrying anti-cancer agents, thus minimizing damage to this important line of body's defence cells, and are discussed.
As these cognitive-enhancing therapeutics enter clinical testing, the need for quantitative and sensitive biomarkers to track cognitive function for both patient selection and for monitoring therapeutic response is critical.
Topics for discussion include selection of monitoring sites, sampling and analytical techniques, and the uncertainty estimation for ambient concentration input data.
The set of diseases and phenotypes provides a starting point for candidate gene approaches and for the selection of biomarkers for monitoring nutrition and health.
The objectives were the kinetic modeling of frozen blueshark slices and arrow squid quality and the selection of suitable TTI for monitoring them in the frozen chain.
The present study suggests that the selection of a method for monitoring streamflow may be based on volume of stream, accuracy of the results, accessibility of the terrain and financial and physical resources available.
Our review suggests that the selection of a method for monitoring streamflow may be based on volume of the stream, accuracy of the method, accessibility of the terrain and financial and physical resources available.
The latter involved the prediction of the potential distribution of the invader using MaxEnt and the selection of priority areas for monitoring the spread of the invader in case of scarcity of resources.
The information derived by this study will have an impact on the immediate translation of HDACi in the pharmacological treatment of DMD patients, as it indicates cellular targets and mechanism of action that will help to the identification of new biomarkers for patient selection in clinical trials and for monitoring the efficacy of the intervention.
